OPENING SHOT

InnovaMatrix Went From $69 Million to $5 Million. Convatec Raised Guidance.

Convatec’s 10-month trading update makes the scale argument in two numbers. The company now expects about $5 million in 2026 InnovaMatrix revenue, down from a previous $5–10 million estimate. InnovaMatrix sold $69 million in 2025. And in the same update, Convatec raised full-year growth guidance to 6.25–7% from 5.5–6.5%. Shares rose about 9%.

The same payment change cut Organogenesis’s revenue 70%. For a $2.4 billion diversified company, it barely registers.

That gap explains most of this week’s news. Essity told investors it wants to buy scale in North American wound care. HMP Global, which runs SAWC and AMP, agreed to sell a majority stake to a private equity firm with $41.9 billion under management and a stated plan to make acquisitions. Sanara grew 8% heading into its MiMedx deal. And companies without scale are building ways around it: shared commercialization, hospital channels, and mergers.

CMS is still setting the rules. It proposed a program integrity rule this week that it plans to repeat every year, and the 2027 payment rules take effect in six weeks. Policy applies to every company equally. Scale decides who can absorb it.

THE SCALE TEST

Company

CAMP exposure

Latest result

Organogenesis

Almost all outpatient wound care

Q3 revenue −70%

MiMedx

Outpatient CAMP plus surgical

Q3 revenue −45%

Convatec

InnovaMatrix, under 3% of 2025 revenue

FY26 guidance raised; InnovaMatrix ~$5M vs. $69M

Sanara

Surgical soft tissue

Q3 revenue +8%, adj. EBITDA +14%

The BTK read: The flat rate didn’t decide who wins, but how much each company had at stake. A product line that was 3% of revenue can go to almost nothing without affecting guidance. The same decline at a company where that line was most of the business becomes a funding problem. That difference in exposure is what buyers are now pricing.

SCALE & CONSOLIDATION

Advanced Wound Care | Convatec Raises Guidance as InnovaMatrix Nearly Disappears

Convatec reported 6.6% organic growth year to date excluding InnovaMatrix, and 3.7% including it. Advanced Wound Care grew low-to-mid single digits excluding InnovaMatrix, with ConvaFoam gaining share and Aquacel AG+ Extra growing slightly ahead of soft markets. The company held its adjusted operating margin guidance at 23% or higher, which absorbs about 90 basis points of InnovaMatrix headwind. Its $200 million buyback remains on track.

The BTK read: Convatec’s wound care performance was steady, not strong. Low-to-mid single digits in soft markets is a share story, not a market recovery. The guidance increase came from Infusion and Continence. What the update shows is that a diversified company can absorb losing a skin substitute line almost entirely, take a 90-basis-point margin hit, keep its buyback, and still raise its outlook. A pure-play CAMP company can’t do any of that.

Advanced Wound Care | Essity Puts North American Wound Care Acquisitions on the Table

At the Jefferies Global Healthcare Conference, Essity named North America an underpenetrated market and advanced wound care, infection management, and complication reduction as Health & Medical priorities. Management raised acquisitions as a way to add wound care scale and capabilities, despite near-term growth and margin pressure. Essity has said in earlier investor settings that its M&A focus is bolt-on deals in Health & Medical, especially advanced wound care and compression. Its last U.S. wound care deal was Hydrofera in 2021. investing.com

The BTK read: Essity is the fifth-largest wound care company globally and wants a bigger U.S. position. The likely targets are companies with differentiated products and established North American channels, and little dependence on the outpatient CAMP rate. Infection management is a clue. Expect bolt-ons in antimicrobial dressings and complication prevention rather than skin substitutes.

Education & Events | HMP Global to Be Acquired by TJC

HMP Global agreed to sell a majority interest to investment funds managed by TJC. Susquehanna Growth Equity, HMP’s partner since 2008, will keep a minority stake. HMP says the deal supports continued investment in existing businesses, new offerings, and strategic acquisitions. It is expected to close in Q4 2026. HMP’s wound care assets include SAWC, AMP, and WoundCon and WoundSource, which came with its 2021 acquisition of Kestrel Health Information. prnewswire

The BTK read: HMP’s events are where much of the wound care and limb salvage industry meets clinicians, launches products, and sets the year’s agenda. A new owner with $41.9 billion under management and an acquisition plan means more of that channel will likely sit under one company. For manufacturers, the things to watch are sponsorship and exhibit costs, how the event calendar develops, and whether independent meetings stay independent. HMP has made three dermatology acquisitions in 18 months, so its playbook is already visible.

Skin Substitutes / CAMP | Sanara Grows 8% Heading Into MiMedx

Sanara reported Q3 revenue of $28.4 million, up 8%, with adjusted EBITDA up 14% to $5.6 million. Growth came from its soft tissue repair portfolio, including CellerateRX Surgical, BIASURGE, and FORTIFY TRG, and from expansion of its independent U.S. distribution network. The MiMedx acquisition is still pending FTC review. yahoo finance

The BTK read: This is the asset MiMedx is buying: surgical, growing, and profitable. It’s the clearest example of an acquirer buying something the flat rate doesn’t touch. The independent distribution network may matter as much as the products, since channel is what MiMedx needs to make surgical its main business.

Commercialization | NOVA Medical Launches a Shared Commercialization Platform

NOVA Medical launched as a tissue repair and regenerative medicine company with a physician-guided commercialization platform covering five stages: Prevent, Assess, Prepare, Restore, and Close. Founded by wound care leaders and plastic surgeons, NOVA connects manufacturers with clinical networks so they don’t have to build their own national sales organizations. 24-7pressrelease

The BTK read: This is one answer to the scale problem. A company without a national sales force uses a shared one. Under a flat rate, where products can’t compete on price, clinical network access becomes the differentiator. The model will be tested on its economics: what a manufacturer gives up for that access, and whether a shared platform can stay credible with clinicians across competing products.

Briefs

  • BioStem Technologies grew hospital revenue for a second straight quarter as customers expanded use of its amniotic and placental portfolio. It’s another company moving toward the hospital setting.

  • Vivo Care and Onpoint Healthcare Partners merged to expand AI-powered remote care services. Merging is another way to get scale, here in remote care.

  • Xtant Medical reported Q3 results and announced a board-led strategic review.

  • Nuo Therapeutics reported Q3 results.

  • Leerink upgraded Abbott and forecast medtech outperformance through 2027, citing valuations near multi-year lows. Sector sentiment matters for wound care companies that need to raise money.

REIMBURSEMENT & POLICY

Enforcement | CMS Proposes CRUSH: A Program Integrity Rule It Plans to Repeat Every Year

CMS proposed the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) rule. It spans Medicare, Medicaid, CHIP, and the Marketplace, and CMS projects nearly $90 billion in savings over 10 years. CMS said it intends to issue program integrity rules like this every year. The proposal tightens provider screening and enrollment, requires prompt self-reporting and return of identified fee-for-service overpayments, and expands ownership transparency. It would also set a single 30-day deadline for reporting all enrollment changes, replacing today’s mix of 30 and 90 days. Comments are due January 19, 2027. The proposal arrived the same day CMS estimated FY2026 improper payments at $112.9 billion, including $34 billion in Original Medicare, up from $28.8 billion. fiercehealthcare

The BTK read: Don’t read this as a wound care rule. CMS officials say most of the projected savings come from expanded audits of Medicare Advantage diagnosis data. What matters for wound care is that enforcement is becoming a standing annual rule. Enrollment, ownership disclosure, and overpayment self-reporting are exactly where the mobile and office-based skin substitute billers of 2023–2025 were weakest. Larger operators with compliance staff will handle this as overhead. Small practices will have to change how they operate.

From the Policy Desk | One Bet, Now Final

My analysis of the CY2027 final rules is out on HMP’s Wound Care Policy News Desk. The short version: 2026 reset the product price, and 2027 holds that price while cutting what the visit around it pays. The main points:

  • Sheet skin substitutes hold at $127.14/cm². Non-sheet products are now nationally priced in the office but stay packaged in the hospital outpatient setting. CMS’s own OPPS rule text and payment file disagree on how their application is paid.

  • The visit pays less. The conversion factor finalized at $32.6286 for most practices, down 2.31%. A modifier-25 E/M billed with a 0-day procedure like debridement or skin substitute application now pays every service except the highest-valued one at 80%.

  • CMS is pricing from what companies publish. It cut the 97610 supply input from $320.18 to $125.00 using the manufacturer’s own investor presentation. It gave fluorescence imaging a national rate under 97611 while the MACs propose non-coverage.

  • The Breakthrough shortcut to pass-through payment is closed for new applications. Wound technologies that planned around it now need to show substantial clinical improvement.

The BTK read: Read this alongside the scale theme. Every lever in the 2027 rules adds cost for the provider: smaller visit payments, more documentation, prior authorization in WISeR states. Large health systems and multi-site practices spread that cost across volume. Single-site practices can’t. Lower visit payments push the market toward larger operators.

CLINICAL & REGULATORY

Skin Substitutes / CAMP | PolarityBio Adds Robert Langer Ahead of SkinTE PDUFA

PolarityBio appointed Moderna co-founder and MIT Institute Professor Robert Langer to its board as it prepares to commercialize SkinTE, its autologous cutaneous multicellular therapy. SkinTE’s BLA was accepted with Priority Review, with a PDUFA date of March 16, 2027. polaritybio

The BTK read: A BLA approval would put SkinTE outside the flat rate. That’s the regulatory premium the Q3 capital data has been showing. One complication: CMS narrowed the Part B inflation rebate exclusion in the CY2027 PFS, so skin substitutes licensed under section 351 will now be subject to rebates. A BLA still carries a premium, but less than it did.

Burns / Acute | AVITA Reports Complete Cohealyx I Full-Thickness Data

AVITA released complete data from its Cohealyx I study in full-thickness wounds. avita

The BTK read: Cohealyx grew 21% to $2.1 million last quarter. Clinical data in full-thickness wounds supports expanding it beyond burns. Look for the endpoints and comparator in the full release.

Skin Substitutes / CAMP | Conexeu Adds Collagen Sheet and Lattice Formats

Conexeu announced early development of W.A.F.E.R. Sheet and W.A.F.E.R. Lattice, collagen scaffold formats that extend its CXU platform beyond its lead flowable candidate. It still plans a 510(k) submission for the flowable device in Q1 2027, and it named Daniel M. Bradbury board chairman. morningstar

The BTK read: Under the CY2027 PFS, a non-sheet product like Conexeu’s flowable is paid at $127.14/cm² in the office and packaged in the hospital. Adding a sheet format gives Conexeu a product that’s paid separately in both settings. Expanding formats is partly a reimbursement decision.

Pharma / Drug | Nova Anchora Raises $23 Million for Topical Collagen VII in DEB

Nova Anchora raised $23 million to advance its topical collagen VII therapy for dystrophic epidermolysis bullosa, a rare genetic blistering disorder that causes chronic wounds. globenewswire

The BTK read: Rare disease, a drug pathway, and a well-defined patient population. This is the kind of wound care asset that’s raising money right now.

AI in Wound Care | Research Moves Toward Practice

  • A study in the Journal of Diabetes Science and Technology reports that an AI smartphone thermal imaging platform predicted DFU healing outcomes from a single image at first presentation, instead of the standard four-week wait. news-medical

  • La Trobe University is piloting AI clinical decision support for wound care in rural Australian health services. la trobe

  • WoundScribe AI launched “On Foot,” wound care software built for podiatry practices. einnews

  • A review found remote patient monitoring tools report high accuracy but lack multi-site testing.

The BTK read: Predicting healing at first presentation would change the timing of treatment decisions, including when to escalate to advanced therapy. The review’s finding is the useful caution: single-site accuracy isn’t validation. Under the 2027 rules, the documentation tools may be easier to sell than the predictive ones, because they help practices meet the new requirements.

📊 Q3 EARNINGS: WHO’S LEFT

Reported since last issue: Convatec (Nov 18, trading update), Sanara, BioStem, Nuo Therapeutics, Xtant Medical.

Date

Company

What to watch

Nov 24

Medtronic (fiscal Q2)

Peripheral and aortic

Nov 26 (indicative)

Aroa (H1 FY27)

Myriad growth, Endoform under Mölnlycke, Symphony launch

Aroa is the last wound care report of the quarter. After that, Q3 is fully in.

📡 BTK Intelligence Dashboard 📡

Wound care, limb salvage, foot and ankle, and vascular: all scored, indexed, and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The Q3 Capital Flow Report is on the platform.

📅 UPCOMING EVENTS

November 24: Medtronic fiscal Q2

November 26: Aroa half-year results (indicative)

December 5–6 | San Antonio, TX: DFUpdate 2026 (Diabetic Foot Update), UT Health San Antonio. Hosted by ALPS, with pre-meeting workshops December 4.

December 9–12 | Phoenix, AZ: Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

December 11: Federal funding deadline, which also decides the WISeR funding rider

January 1, 2027: CY2027 PFS and OPPS final rules take effect

January 19, 2027: CRUSH proposed rule comment deadline

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

-Scott

Recommended for you

View all
caret-right